-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Initiates Coverage On Generate Biomedicines with Buy Rating, Announces Price Target of $30

Benzinga·03/24/2026 11:37:37
Listen to the news
Guggenheim analyst Seamus Fernandez initiates coverage on Generate Biomedicines (NASDAQ:GENB) with a Buy rating and announces Price Target of $30.